Navigation Links
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
Date:5/5/2008

as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.

Please see complete prescribing information at http://www.synagis.com.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
2. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
3. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... and PHOENIX , Aug. ... to bring cutting-edge next-generation sequencing and proteomic diagnostics ... today announced a collaboration with TESARO, Inc.  Paradigm ... patient tissue samples from clinical trials to better ... to TESARO,s TSR-011.  This may lead to more successful ...
(Date:8/20/2014)... ApolloDx™ today announced it will unveil and ... event at the company,s office in Salt ... The event, which will start at 10:00 a.m., will ... .    "We believe our mobile diagnostic ... , Co-Founder and Managing Partner of ApolloDx. In addition ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
Breaking Medicine Technology:Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... COGENT-1 Study of CGT-2168 Expands to Europe; Focus ... Gastrointestinal Side Effects of Antiplatelet Therapy, ... Pharmaceuticals,Inc. today announced that the first patient has ... 3 study of its novel combination medicine,CGT-2168. The ...
... Motion Technologies,announced the completion of the first surgical ... System (TM) (TSMS(TM)), the first total,joint replacement system ... and posterior dynamic stabilization device (PDS). The,successful procedure ... Numune,Education and Training Hospital by Dr. Erkan Kaptanoglu, ...
Cached Medicine Technology:European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals 2Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device 2
(Date:8/20/2014)... According to the new report “Engineering ... Fluor polymer, Polyamide, Polycarbonate, Polyoxymethylene, Thermoplastic Polyesters, ... & Forecasts (2013- 2018)”, defines and segments ... and forecasting of the global revenue and ... restraining factors for the global engineering plastics ...
(Date:8/20/2014)... FL (PRWEB) August 20, 2014 Ticket Down ... tickets in Miami, FL at the Sun Life Stadium in ... football rivalry this September when Brazil and Colombia meet at Sun ... of the top 10 teams in the world and will be ... in Brazil. The match will kick-off on Sept. 5 and will ...
(Date:8/20/2014)... IQ Formulations , a top national health and nutritional ... , distinguishing it as one of the fastest growing private ... the list, but was ranked in the top 50 by ... It also ranked ninth among all health companies, fifth among ... growing company in the Miami metro area. , Headquartered ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... 20, 2014 The Institute for ... is proud to announce its new partnership with ... a cutting-edge university offering graduate programs featuring flexible ... Program are now eligible to receive six graduate ... Health Studies. , “I’m so thrilled to announce ...
Breaking Medicine News(10 mins):Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 2Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 3Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 4Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... (NYSE AMEX: ULU ) today announced ... The Company reported a net loss of $3.1 million, or ... or $0.03 per share, for the same period last year. ... of $5.1 million, compared with $7.6 million at December 31, 2009.Commenting ...
... Calif., May 15 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... former chief operating officer of Boston Scientific, to its ... shareholders at the company,s annual shareholders, meeting on May ...
... DALLAS, May 15 C. Richard Boland, M.D., chief ... at Dallas, has been named vice president of the ... evolve into the presidency in 2011. The oldest medical ... dedicated to advancing the science and practice of gastroenterology. ...
... The International Union for Health Promotion and ... (SOPHE) are pleased to release today special, complementary peer-reviewed ... assurance systems of global capacity in health promotion and ... Behavior (Vol. 36, No. 3, June 2009), and ...
... American Institute of Ultrasound in Medicine is pleased to ... Edition . All operators of ultrasound systems with an ... The book consists of 3 parts: Bioeffects and Biophysics, ... achievable). With the information from this 64 page publication, ...
... Nyer Medical Group, Inc. (Nasdaq: NYER ) ... 2009. Revenues for third quarter of fiscal 2009 increased ... as reported for the comparable quarter in the prior year. ... addition of five new pharmacies over the past 12 months. ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 6Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 2Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 3Health News:Dallas Gastroenterologist Named Vice President of Prestigious National Organization 2Health News:Special journal issues released on global health promotion and health education 2Health News:AIUM releases second edition of 'Medical Ultrasound Safety' 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 3Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 4Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 5
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Round, knurled handle with polished finish and straight shaft. 1 mm ring curette 1.5 mm high, 33 mm shaft. Overall length: 5.1 inches....
Medicine Products: